Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorobenzene SCHEMBL15544432 | 0.86 | NFE2L2 (0.53) | NFE2L2CA4CA14CA6CA5A | |
| Fluorobenzene SCHEMBL7024891 | 0.86 | — | — | |
| Fluorobenzene SCHEMBL27957654 | 0.86 | NFE2L2 (0.53) | NFE2L2CA4CA14CA6CA5A | |
| Fluorobenzene SCHEMBL12363 | 0.86 | — | — | |
| Fluorobenzene SCHEMBL14012524 | 0.86 | — | — | |
| SCHEMBL22526495 | 0.86 | NFE2L2 (0.53) | NFE2L2CA4CA14CA6CA5A | |
| SCHEMBL3318481 | 0.83 | BCL2L1 (0.50) | NFE2L2TDP1CA1CA2BCL2L1 | |
| Fluorobenzene SCHEMBL27553303 | 0.83 | — | — | |
| Fluorobenzene SCHEMBL28178880 | 0.83 | — | — | |
| Fluorobenzene SCHEMBL15754920 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483291-B | Synthesis method of (E) -beta-aryl-beta, gamma-unsaturated ester compound | 安阳师范学院 | 2021-09-10 | — | — | CN | claimed |
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12448406-B2 | Fused ring carbazole tetradentate metal platinum (II) complex and use thereof | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2025-10-21 | — | — | US | disclosed |
| EP-4501940-B1 | FUSED RING CARBAZOLE TETRADENTATE METAL PLATINUM (II) COMPLEX AND USE THEREOF | UNIV ZHEJIANG TECHNOLOGY (CN) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025137437-A1 | SOLID FORMS OF A GABAA RECEPTOR MODULATOR AND METHODS OF ITS USE | PFIZER INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20250059223-A1 | FUSED RING CARBAZOLE TETRADENTATE METAL PLATINUM (II) COMPLEX AND USE THEREOF | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4501940-A1 | FUSED RING CARBAZOLE TETRADENTATE METAL PLATINUM (II) COMPLEX AND USE THEREOF | Zhejiang University of Technology (CN) | 2025-02-05 | — | — | EP | disclosed |
| EP-4438042-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | Ohio State Innovation Foundation (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294477-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-05 | — | — | US | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| US-6028112-A | Spirocyclopropyl fluorenes as melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999062899-A1 | TETRAHYDROINDOLONE DERIVATIVES AS GABAAALPHA5 LIGANDS FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-09 | — | — | WO | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998052554-A1 | SPIROCYCLOPROPYL FLUORENES AS MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| CN-1131945-A | Arthropodicidal oxazolines and thiazolines | DU PONT (US) | 1996-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | SIGMAR1, OPRL1, OPRM1 | NFE2L2 1279/4885CA4 4604/4885CA14 4807/4885 |
| US-20250059223-A1 | FUSED RING CARBAZOLE TETRADENTATE METAL PLATINUM (II) COMPLEX AND USE THEREOF | OCIAD2, OCIAD1, OSTC | NFE2L2 1307/4885CA4 2266/4885CA14 2422/4885 |
| US-20240294477-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | NFE2L2 1714/4885CA4 1348/4885CA14 1669/4885 |
| US-12448406-B2 | Fused ring carbazole tetradentate metal platinum (II) complex and use thereof | OCIAD2, OCIAD1, OSTC | NFE2L2 1307/4885CA4 2266/4885CA14 2422/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | NFE2L2 2502/4885CA4 230/4885CA14 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.